Peoples Bank OH maintained its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,389 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Peoples Bank OH’s holdings in Bristol-Myers Squibb were worth $690,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BMY. Waldron LP acquired a new stake in Bristol-Myers Squibb in the 1st quarter valued at $475,000. Founders Capital Management LLC increased its holdings in Bristol-Myers Squibb by 0.7% in the 1st quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 29 shares in the last quarter. Headinvest LLC increased its holdings in Bristol-Myers Squibb by 23.1% in the 1st quarter. Headinvest LLC now owns 12,675 shares of the biopharmaceutical company’s stock valued at $689,000 after purchasing an additional 2,375 shares in the last quarter. Sit Investment Associates Inc. increased its holdings in Bristol-Myers Squibb by 3.5% in the 1st quarter. Sit Investment Associates Inc. now owns 9,175 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 312 shares in the last quarter. Finally, NBT Bank N A NY increased its holdings in Bristol-Myers Squibb by 0.7% in the 1st quarter. NBT Bank N A NY now owns 121,122 shares of the biopharmaceutical company’s stock valued at $6,587,000 after purchasing an additional 879 shares in the last quarter. Hedge funds and other institutional investors own 68.88% of the company’s stock.

Bristol-Myers Squibb Company (BMY) opened at 64.81 on Friday. The stock’s 50 day moving average is $61.56 and its 200 day moving average is $56.65. The company has a market cap of $106.28 billion, a PE ratio of 23.67 and a beta of 1.19. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $65.03.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter in the previous year, the firm posted $0.69 EPS. The business’s revenue was up 5.6% compared to the same quarter last year. Equities analysts predict that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be issued a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.41%. Bristol-Myers Squibb’s payout ratio is 56.73%.

Several brokerages recently issued reports on BMY. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Jefferies Group LLC reiterated a “buy” rating and issued a $72.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price target for the company. in a report on Thursday, September 28th. Finally, UBS AG reiterated a “buy” rating and issued a $72.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a report on Friday. One analyst has rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $62.38.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at approximately $2,777,820. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Theodore R. Samuels II acquired 6,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now owns 18,000 shares in the company, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/08/peoples-bank-oh-has-690000-stake-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.